--- title: Features Interpretation --- [Skip to content](https://www.emgenex.com/features-interpretation#main-content) [![Layer 1](https://www.emgenex.com/hubfs/Layer%201.svg "Layer 1")](https://emgenex.com/) - [Home](https://www.emgenex.com/) - Solutions - ###### [Lab Information System Modern LIS/LIMS](https://www.emgenex.com/lis) - ###### [Pharmacogenomics Research Analysis and Decision Support](https://www.emgenex.com/pgx) - ###### [Telegenetics Virtual Genomic Platform](https://www.emgenex.com/telegx) - ###### [Lab Billing Service Revenue Cycle Management](https://www.emgenex.com/lab-revenue-cycle-management) - [About Us](https://www.emgenex.com/about-us) - [Careers](https://www.emgenex.com/career) - [Blog](https://blog.emgenex.com/blog-page) [Get in Touch](https://www.emgenex.com/contact-us) [Get in Touch](https://www.emgenex.com/contact-us) [Pharmacogenomics](https://new.emgenex.com/pgx) > **Research Analysis** ## Transform genomic data into PGx insights. Our service provides tailored pharmacogenomics research analysis, designed to enhance decision-making capabilities for healthcare providers. ![Logo Icon](https://www.emgenex.com/hubfs/Genoscribe/logo_icon.svg) ## Take advantage of pre-designed templates or customize them to fit your exact specifications. CURRENT MEDICATIONS DRUG SUMMARY DETAILED ANALYSIS COLLOBORATIVE EXCHANGE GENE SUMMARY DRUG INTERACTION ##### Reporting available on ## 250 + Drugs ## 80 + Genes ![Frame 150](https://www.emgenex.com/hubfs/Frame%20150.webp) ![Frame 1968](https://www.emgenex.com/hubfs/Frame%201968.webp) ![Frame 2019](https://www.emgenex.com/hubfs/Frame%202019.webp) ![Frame 1973](https://www.emgenex.com/hubfs/Frame%201973.webp) ![Frame 1998](https://www.emgenex.com/hubfs/Frame%201998.webp) ![Frame 1975](https://www.emgenex.com/hubfs/Frame%201975.webp) [Download Sample Report](https://www.emgenex.com/features-interpretation#popup-form) ### Download Sample Report ![image-1](https://www.emgenex.com/hubfs/image-1.svg) ### Upload data files to the cloud platform or direct data integration with lab equipment. Our goal is to minimize the manual work to optimize scalability and efficiency in lab operations. We can integrate with popular instruments from Thermofisher, Illuminia, and others. ![img16](https://www.emgenex.com/hubfs/Genoscribe/img16.png) ### Send pdf report or discrete data to electronic health records. Some of our already-established integrations ![meditech](https://www.emgenex.com/hs-fs/hubfs/Genoscribe/meditech.png?width=134&height=40&name=meditech.png) ![epic](https://www.emgenex.com/hs-fs/hubfs/Genoscribe/epic.png?width=70&height=40&name=epic.png) ![KIPU](https://www.emgenex.com/hs-fs/hubfs/Genoscribe/KIPU.png?width=70&height=40&name=KIPU.png) ### Everything is possible with the right capabilities. Here you will find commonly asked questions. How many days it would take to set up for a lab? Depending on the specific data file types and the SNPs tested, it may take 1 to 3 weeks to go live. Can PGx research reporting integrate with EHR? Yes. We already have established integrations with various EHRs.  Which pharmacogenomic testing panels are available? We customize reporting based on any gene panel available from Thermo Fisher and other vendors. Do you offer customizable reporting options? Yes. We work with your team to designing a report that meets your requirements. Is there a provider portal to distribute reports? Yes. Reports are delivered using our LIS provider portal. What is the scope and purpose of PGx research services? Emgenex offers a range of general-purpose research services suitable for various needs. The analyses provided by Emgenex are solely for educational and research use. We ensure that all advice from Emgenex is transparent and backed by citations from existing publications, which are available for independent verification. Emgenex's analysis of literature in the field of pharmacogenomics emphasizes that this area of knowledge is constantly evolving. New studies regularly emerge, either refining existing guidelines or introducing entirely new insights. It is important for researchers and other individuals who rely on pharmacogenomics reference data, including any meta-analyses produced by Emgenex, to be aware of and understand the limitations inherent in these ongoing developments. How does research analysis differ from lab reporting? Emgenex's PGx research analysis is separate from the laboratory CLIA reports on genetic variations. It serves as an independent literature review carried out by professional researchers. This analysis is not intended for clinical reporting purposes; instead, its aim is to efficiently present pertinent medical reference information for educational purposes to its users. ### Want to see our PGx platform capabilities in action? Set up a personalized demo session. [Book a demo](https://www.emgenex.com/features-interpretation#first-popup) ### Easy integration with your LIS system. Want to see a demo? Set up a personalized demo session. [Book a demo](https://www.emgenex.com/features-interpretation#first-popup) ### Book a demo ![Layer 1](https://www.emgenex.com/hubfs/Layer%201.svg "Layer 1") Email: [info@emgenex.com](mailto:info@emgenex.com) Tel: [(609) 235-1600](tel:(609)%20235-1600) Solutions - [Lab Information System](https://www.emgenex.com/lis) - [Pharmacogenomics](https://www.emgenex.com/pgx) - [Telegenetics](https://www.emgenex.com/telegx) - [Lab Billing Service](https://www.emgenex.com/lab-revenue-cycle-management) Company - [About Us](https://www.emgenex.com/about-us) - [Blog](https://blog.emgenex.com/blog-page) - [Contact Us](https://www.emgenex.com/contact-us) Why Us Benefit from our decade-long expertise in the lab industry, driven by cutting-edge science and technology. ©2026 by Emgenex Inc. [Follow us on Facebook](https://www.facebook.com/Emgenex) [Follow us on LinkedIn](https://www.linkedin.com/company/emgenex/) - [Privacy Policy](https://www.emgenex.com/privacy-policy) - [Terms of Use](https://www.emgenex.com/terms-and-conditions)